Examples of 'b-amyloid' in a sentence
Meaning of "b-amyloid"
B-amyloid is a noun referring to a protein that accumulates in the brains of people with Alzheimer's disease
How to use "b-amyloid" in a sentence
Basic
Advanced
b-amyloid
The formation of B-amyloid peptide is normal physiological process.
It is another object of the invention to prevent deposition of B-amyloid.
Immunizations of patients with B-amyloid are in the experimental stage of a therapy.
Intact cultured cells provide a source of B-amyloid peptide.
Soluble B-amyloid is thought to translocate between blood and cerebrospinal fluid.
This method can be used to generate catalytic antibodies to B-amyloid.
It is produced by enzymic cleavage from B-amyloid protein precursor protein.
Oxidation damage is involved in the cell death due to B-amyloid.
Deposited B-amyloid can be assessed biochemically or by counting amyloid deposits and plaques.
Other known biomarkers are tau protein and B-amyloid proteins.
The neurotoxicity of B-amyloid has been associated with the fibrillogenic properties of protein.
Said brain tissue comprises for example B-amyloid deposits.
The neurotoxicity of B-amyloid has been associated with the fibrilogenic properties of protein.
The intercellular protein clusters or plaques are composed of deposits of B-amyloid protein.
These animals have the B-amyloid plaques on the pancreas instead of brain.
See also
Lymphocytes were examined for cytokine production in vitro in the presence of B-amyloid.
The oligonucleotides encode the B-amyloid epitope with a glycine adaptor sequence,.
This first antibody is covalently linked to an antibody which binds B-amyloid.
The invention also provides B-amyloid modulator compound comprising a formula, wherein.
A somewhat similar peptide is present in a region of the B-amyloid precursor polypeptide.
In one embodiment, the B-amyloid modulator compound and the biological sample are contacted in vitro.
Preferably the treatment is for a condition associated with the deposition of B-amyloid.
A method according to claim 6 for labeling B-amyloid plaques and neurofibrillary tangles.
Pathological features of Alzheimer 's disease concern senile plaques that are deposits of B-amyloid.
Said brain tissue comprises for example B-amyloid plaques and / or neurofibrillary tangles.
Such a sample composition might be contaminated with a pathogenic form of B-amyloid protein.
The soluble and insoluble forms of B-amyloid present within an animal are in dynamic equilibrium.
Also, brain hippocampal neurons are protected from cell death induced by B-amyloid.
Insoluble B-amyloid aggregates deposit from the soluble pool in the brain, as amyloid plaques.
Determining the presence and / or amount of pathogenic B-amyloid protein within the sample.
A compound of claim 7 wherein said treatment is for a condition associated with the deposition of B-amyloid.
The decrease approximates the reduction of B-amyloid identified with immuno-staining in the cortex.
The vaccine proposed in the present invention is a new analogue of the B-amyloid peptide.
Both AChE and B-amyloid activate macrophages.
The antibodies are catalytic antibodies which catalyze hydrolysis of B-amyloid at a predetermined amide linkage.
In another embodiment B-amyloid is bound to an immunoassay plate in an ELISA assay.
Congo red was found to form at least two distinct complexes with B-amyloid in vitro.
A series of N - terminally modified B-amyloid peptides was synthesized using standard methods.
In another embodiment, a combination of antibodies having specificity for various regions of B-amyloid are administered.
Both AChE and B-amyloid enhance calcium entry through NMDA receptors.
Such a clearance mechanism would lead to a continuous cycling of B-amyloid out of the brain.
The B-amyloid modulator compounds described herein are summarized in the following Table.
These deposits are the intracellular neurofibrillary tangles and the extracellular B-amyloid plaques.
Formation of B-amyloid may impair the coupling of the muscarinic receptor with G-proteins.
A variety of art known methods can be employed to determine the amount of B-amyloid present.
Recent studies have demonstrated that B-amyloid increases the GSK3B activity and tau protein phosphorylation.
Another aspect of the invention pertains to a method for selecting a modulator of B-amyloid aggregation.
B-amyloid aggregation results in enhanced emission of Thioflavin-T.
Preferably the condition is a neurological disease having associated B-amyloid deposition such as Alzheimer 's disease.
The Exemplification details the production of vectorized bispecific antibodies which bind B-amyloid.
